期刊文献+

氯沙坦联合福辛普利治疗充血性心力衰竭疗效观察 被引量:1

The clinical efficacy of losartan combined with fosinopril on the treatment of congestive heart failure
在线阅读 下载PDF
导出
摘要 目的 :探讨氯沙坦联合福辛普利治疗慢性充血性心力衰竭 (CHF)的临床疗效。方法 :82例CHF患者随机分成治疗组和对照组。治疗组40例给予氯沙坦50mg/d ,福辛普利10mg/d ,对照组给予福辛普利10mg/d ,及安慰剂治疗。两组基础治疗类同 ,疗程6个月。观察治疗前后两组患者的临床症状 ,超声心动图心功能指标 ,6分钟步行距离的变化及不良反应。结果 :两组治疗前后相比左室射血分数 (LVEF)、6分钟步行距离均有显著改善 (P<0.01〉 ,治疗组LVEF及6分钟步行距离的发送优于对照组。结论 :氯沙坦联合福辛普利治疗CHF可以增强疗效。 Objective:To evaluate the clinical therapeutic efficacy of losartan combined with fosinopril on the treatment of congestive heart failure(CHF).Methods:Using random and single blind contrast during the period of month,we divided82patients with CHF into the treatment group(n=40)and the control group(n=42),The clinical therapeutic efficacy,LVEF,6min walk trial and adverse reactions were anaˉlyzed.Results:The clinical prognosis and LVEF,6min walk tril of the patient in the two group were all significantly ameliorated compared with those of the patient before treatment(P<0.01).Improvement of symptom in treatment group was better than that in control group.Conclusion:losartan combined with fosinopril has obvious effects on treating patient with CHF.
作者 潘博希
出处 《现代医药卫生》 2005年第4期387-388,共2页 Journal of Modern Medicine & Health
关键词 氯沙坦 福辛普利 充血性心力衰竭 药物治疗 Congestive heart failure Losartan Fosinopril
  • 相关文献

参考文献5

二级参考文献51

  • 1[1]Carelock J, Clark AP. Heart Failure: pathophysiolngic mechanisms[J].Am J Nurs,2001,101(12) :26.
  • 2[2]Kim S, Yoshiyama M, Izumi Y, et al. Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remolding[J].Circulation, 2001,103: 148.
  • 3[3]Unger T.Neurohormonal modulation in cardiovascular disease[J] .Am Heart J,2000, 139(1) :2.
  • 4[4]Wei CC, Meng QC, Palmer R, et al. Evidence for angiotensin converting enzyme and chymase mediated angiotensin Ⅱ formation in the interstitial fluid space ofthe dog heart in vivo[J]. Circulation, 1999,99: 2583.
  • 5[5]Mial S, Loke KE, Slater JP, et al. synergy of anlodipine and angiotensin converting enzyme inhibitors in regulating myocardial oxygen consumption in normal canine and failing human heart[J] .Am J Cardiol, 1999, 83:92.
  • 6[6]Kawano H, Do YS, Kawano Y, et al.angiotensin Ⅱ has multiple profibrotic effects in human cardiac filroblasts[J]. Circulation, 2000,101: 1130.
  • 7[7]Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin Ⅱ type 2 receptor research in the cardiovascular system[J] .Hypertension,1999,33:613.
  • 8[8]Jalowy A, Schulz R, Dorge H, et al.Infract size reduction by AT1-receptor blockade through a signal cascade of AT2 - receptor activation,bradykininand prostaglandins in pigs[J] .J Am Coll Cardiol, 1998,32:1787.
  • 9[9]Bjom Dahlof. Left ventricular hypertrophy and angiotensin Ⅱ antagonist[J].Am J Heart,2001,14:174.
  • 10[10]Matsubara H. pathophysiological role of angiotensin Ⅱ type 2 receptor in cardiovascular and renal disease[J]. Circulation research, 1998,83(12): 1182.

共引文献35

同被引文献27

  • 1吴浩,翟所迪.血管紧张素转化酶抑制剂与血管紧张素受体阻滞剂治疗充血性心力衰竭的系统评价[J].中国循证医学杂志,2005,5(3):196-205. 被引量:8
  • 2程五福,李锋,程龙献.替米沙坦联合贝那普利治疗充血性心力衰竭的疗效观察[J].心血管康复医学杂志,2005,14(4):355-356. 被引量:3
  • 3黄绍湘,卫智权,何贵新,黎芳,卢幻真.坎地沙坦及培哚普利对慢性心力衰竭心功能及左室重塑的影响[J].内科,2007,2(3):322-324. 被引量:5
  • 4Pina IL,Apstein CS,Balady GJ,et al.American Heart Association Committee on exercise,rehabilitation,and prevention.Exercise and heart failure:A statement from the American Heart Association Committee on exercise,rehabilitation,and prevention[J].Circulation,2003,107(8):1210-1225.
  • 5Hamroff G,Blanfarb,Mancini D,et al.Angiotensin Ⅱ receptor blockade further reduces afterload safely in patients m aximally lreated with angiotensin converting enzyme inhibitor for heart failure[J].J Cardiovasc Pharmacol,1997,30(4):533-536.
  • 6Averill DB,Diz DI.Angiotensin peptides and baroreflex control ofsympathetic outflow:pathways and mechanisms of the medulla oblongata[J].Brain Res Bull,2000,51(2):119-128.
  • 7Cohn JN,Tognoni G.A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure[J].N Engl J Med,2001,345(23):667-675.
  • 8Pfeffer MA,Swedberg K,Granger CB,et al.Effects of candesartan on mortaliy and morbidity in patients with heart failure the CHARM-overall pregramme[J].lancet,2003,362(9386):759-766.
  • 9Urata H,Boehm KD,Philip A,et al.Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart[J].J Clin Invest,1993,91(4):1269-1281.
  • 10The Cochrane Collaboration.Cochrane handbook for systematic reviews[M/OL].New York:John Wiley & Sons,Ltd,2008.http://cochrane-handbook.org.

引证文献1

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部